Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Public ClinicalTrials.gov record NCT01208662. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. In this study, HDT as compared to conventional dose treatment would be considered superior if it significantly prolongs progression-free survival by at least 9 months or more, recognizing that particular subgroups may benefit more compared to others.
Study identification
- NCT ID
- NCT01208662
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 729 participants
Conditions and interventions
Conditions
Interventions
- Lenalidomide Drug
- Bortezomib Drug
- Dexamethasone Drug
- Autologous Stem Cell Transplant Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2010 (Type not available)
- Primary completion
- Feb 2022 (Actual)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Jan 22, 2026
2010 – 2026
United States locations
- U.S. sites
- 46
- U.S. states
- 23
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Arizona Comprehensive Cancer Center | Tucson | Arizona | 85724 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California at San Diego | La Jolla | California | — | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Stanford University | Stanford | California | 94305 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| University of Florida | Gainesville | Florida | 32608 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Mountain States Tumor Institute at St. Luke's Regional Medical Center | Boise | Idaho | 83712 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Ochsner Foundation Clinic | New Orleans | Louisiana | 70121 | — |
| Eastern Maine Medical Center | Brewer | Maine | 04412 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Cape Cod Healthcare | Hyannis | Massachusetts | 02601 | — |
| Newton-Wellesley Hospital | Newton | Massachusetts | — | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| New Hampshire Oncology and Hematology | Concord | New Hampshire | — | — |
| New Hampshire Oncology and Hematology | Hooksett | New Hampshire | — | — |
| New Hampshire Oncology and Hematology | Laconia | New Hampshire | — | — |
| State University of New York Downstate Medical Center | Brooklyn | New York | — | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| North Shore Long Island Jewish Health System | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health and Sciences | Portland | Oregon | — | — |
| University of Pennsylvania Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt University | Nashville | Tennessee | 37203 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | — | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01208662, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01208662 live on ClinicalTrials.gov.